Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced that the first group of patients has been dosed in a pivotal Phase 2 clinical trial evaluating its QTORINâ„¢ 3.9% rapamycin …
Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment Read More